Navigation Links
Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
Date:2/24/2011

WEDNESDAY, Feb. 23 (HealthDay News) -- A new drug called denosumab (Xgeva) performed somewhat better than the current standard treatment of zoledronic acid (Zometa) for preventing fractures and other bone problems in men with hormone-resistant prostate cancer, a new study suggests.

In many patients, prostate cancer becomes resistant to initial hormone treatment within the first few years of diagnosis. As a result, tumors begin to grow again and spread to other parts of the body, including bones. This increases the risk of fractures and other bone problems that cause pain and disability, which can greatly reduce a man's quality of life, according to background information in the study.

Helping to prevent these bone troubles can prove very important to these patients, one expert said.

"The successful treatment of osteoporosis, bone pain, and complications of advanced boney disease in men with [castration]-resistant prostate cancer will increase their quality of life considerably," noted Dr. Elizabeth Kavaler, a urology specialist at Lenox Hill Hospital in New York City. She was not involved in the new study.

The research, which was funded by Xgeva's maker, Amgen, was led by Dr. Karim Fizazi of the University of Paris Sud, in France, and included more than 1,900 men. The men were treated for hormone-resistant prostate cancer at 342 centers in 39 countries. They were randomly assigned to receive either 120 milligrams of denosumab, delivered subcutaneously (needle just under the skin) plus an intravenous placebo (950 patients) or 4 milligrams of IV zoledronic acid plus IV placebo (951 patients), given every four weeks.

All the patients were advised to take supplemental calcium and vitamin D to help strengthen their bones. This advice was followed by 90 percent of patients in the denosumab group and 87 percent of those in the zoledronic acid group.

The median time to the first bone problems was just under 21 months in the denosumab group and a little more than 17 months in the zoledronic acid group.

Overall, bone problems occurred in 36 percent of patients who took denosumab and 41 percent of those who took zoledronic acid.

"The 5 percent reduction in skeletal related events, including pathologic fractures and spinal cord compression, seen in the denosumab group versus the zoledronic acid group is very encouraging," Kavaler said. "This is a difficult patient population in that their symptoms related to bone metastases can be debilitating."

Serious adverse events were recorded in 63 percent of patients in the denosumab group and 60 percent of those in the zoledronic acid group.

Of the adverse events most likely related to the treatments, hypocalcaemia (very low calcium concentrations) occurred in 13 percent of patients taking denosumab and in 6 percent of those taking zoledronic acid, while osteonecrosis of the jaw (a debilitating destruction of bone tissue) occurred in 2 percent of the denosumab group and 1 percent of the zoledronic acid group.

The study appears online Feb. 24 in the journal The Lancet.

More information

The U.S. National Cancer Institute has more about prostate cancer.

-- Robert Preidt

SOURCES: Elizabeth Kavaler, MD, urology specialist, Lenox Hill Hospital, New York City; The Lancet Oncology, news release, Feb. 24, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
2. Decrease in suicide not linked to newer antidepressants
3. Newer Drugs Beat Gleevec in Head-to-Head Trials
4. In infant heart surgery, newer technique yields better survival in first year of life
5. Newer Genetic Info Adds Little to Predicting Breast Cancer
6. Newer Blood Thinner Beats Plavix for Bypass Patients
7. Newer Genetic Test for Autism More Effective
8. Newer Blood Test Predicts Diabetes, Heart Disease
9. Newer cornea transplant surgery shows short- and long-term promise
10. Antioxidants in pecans may contribute to heart health and disease prevention
11. Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology: